rAAVen Therapeutics develops novel adeno-associated virus (AAV) vectors using advanced cloning, DNA barcoding, and next-generation sequencing techniques to enable precise targeting of specific cell populations for gene therapy applications. The company addresses the need for effective gene delivery systems that can be tailored to treat a wide range of genetic disorders in mammalian models.
Funding
Funding not disclosed
Founders
Product
Problem
Current adeno-associated virus (AAV) vectors often lack the specificity needed for targeted gene therapy, leading to off-target effects and reduced therapeutic efficacy. Developing AAV vectors that can precisely target specific cell populations remains a significant challenge in the field of gene therapy.
Solution
rAAVen Therapeutics develops novel AAV vectors using its rAAptr platform, which combines AAV peptide display with DNA barcoding and next-generation sequencing. This approach enables the screening of millions of rationally designed, targeted AAV variants to identify vectors with high specificity for defined cell populations. The company's technology facilitates the creation of AAV vectors tailored to specific tissue types, cell populations, or applications, improving the precision and effectiveness of gene therapies. rAAVen offers screening of AAV peptide libraries in animal models, including rodents and non-human primates, to ensure translational potential.
Target Audience
rAAVen's primary customers are researchers and companies involved in gene therapy development who require highly specific and efficient AAV vectors for preclinical and clinical applications.
Features
- rAAptr platform for rational design and screening of AAV peptide display libraries
- Unique DNA barcoding and next-generation sequencing for high-throughput AAV variant analysis
- Customizable AAV vector design for targeting specific tissue types, cell populations, or applications
- Screening in animal models (rodents to non-human primates) to validate translational potential
- Ability to combine AAV peptide display with promoter and enhancer elements for increased cell and tissue-specific expression
- Streamlined rational design approach mimicking natural protein-protein interactions